Nike posts flat Q3 fiscal 2026 revenue of $11.3B
NIKE (NYSE:NKE) reported financial results for its fiscal 2026 third quarter ended February 28, 2026, on Tuesday, March 31, 2026.
Todas as matérias desta categoria, das mais recentes às mais antigas.
NIKE (NYSE:NKE) reported financial results for its fiscal 2026 third quarter ended February 28, 2026, on Tuesday, March 31, 2026.
Dave & Buster's Entertainment (NASDAQ:PLAY) reported financial results for the fourth quarter and fiscal year ended February 1, 2026, on Tuesday, March 31, 2026.
nCino (NASDAQ:NCNO) reported robust financial results for its fiscal year 2026 on Tuesday, March 31, 2026, demonstrating continued momentum in the global digital transformation of banking.
Chagee Holdings (NASDAQ:CHA) announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026.
Phoenix Asia Holdings (NASDAQ:PHOE) reported unaudited financial results for the six-month period ended September 30, 2025, on Tuesday, revealing a challenging start to the fiscal year defined by compressed margins and lower top-line volume.
Bitfarms (NASDAQ:BITF) announced transformative full-year 2025 financial results and a major corporate restructuring on Tuesday, March 31, 2026, headlined by a shareholder-approved plan to redomicile to the United States and rebrand as Keel Infrastructure.
Novo Nordisk (NYSE:NVO) announced a strategic shift in its commercial approach on Tuesday, March 31, 2026, launching a multi-month subscription program for its flagship obesity medication, Wegovy.
McCormick & Company (NYSE:MKC) and Unilever announced a landmark agreement on Tuesday, March 31, 2026, to combine McCormick with Unilever’s global foods business.
Forum Markets (NASDAQ:FRMM), a fintech company focused on real-world asset tokenization, reported its fourth-quarter and full-year 2025 financial results and provided 2026 guidance on its scaling RWA platform.
Reading International (NASDAQ:RDI), a company engaged in cinema exhibition and real estate development, reported its fourth-quarter and full-year 2025 financial results.
OS Therapies (NYSE:OSTX) announced on Tuesday, March 31, 2026, that it has reached a pivotal regulatory milestone by submitting its Phase 2b clinical and biomarker data to the U.S. Food and Drug Administration (FDA) for a formal Pre-BLA (Biologics License Application) meeting.
NervGen Pharmaceutics (NASDAQ:NGEN) reported its full-year 2025 financial and operational results on Tuesday, March 31, 2026, marking a definitive shift toward pivotal-stage clinical development.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade